Though much of what causes rheumatoid arthritis (RA) still remains a mystery, what we do know is that RA occurs when the immune system attacks the body's joints. According to recent research, B-cells—a type of white blood cell found in the immune system—are believed to play an important role in causing this attack.

The goal of targeted B-cell therapy is to selectively reduce specific B-cells in the body. This can limit the immune system's attack, and ultimately, the pain and symptoms of RA.

The recent focus on B-cells has led to the development of Rituxan^® (rituximab)—the only treatment that targets B-cells to treat moderate to severe RA. Since it was approved by the FDA in 2006, Rituxan has worked well for many people who haven't been helped enough by other types of treatments. To learn more, visit www.Rituxan.com/RA.

If you're considering Rituxan with your rheumatologist, tell him or her about all of your medical conditions, including any infections you may have or any vaccinations you are scheduled to receive. You should not receive live vaccinations after you receive Rituxan. And you should not receive Rituxan if you have any serious infections. For more information about what to discuss, including the potential benefits and risks, review the Rituxan Medication Guide.